Menu Close

Photobiomodulation for Alzheimer’s disease with modulated 1070-nm light

AD is associated with progressive impairments in memory, language, orientation, and other cognitive skills that affect daily activities throughout the disease course, ultimately leading to death. There is a dire need for effective therapeutic strategies for AD treatment. PBM refers to the low-power light (1–500 mW) in the visible and near-infrared (NIR) spectra to trigger beneficial biological processes in cells and tissues, leading to physiological alterations. PBM has been considered as a promising approach for AD, while its exact mechanism is still unclear.